« Pharmaceutical Shortages in Greece |
| Whitesides on Discovery and Development »
December 7, 2012
The Worst Biotech CEO?
Adam Feuerstein at TheStreet.com has his yearly readers' pick for "Worst Biotech CEO". This year's winner is Jim Bianco of Cell Therapeutics, and there seems to be a good case:
Bianco, a longtime worst biotech CEO nominee, broke through this year and finally shoved his way into loser's circle by managing to engineer a 77% drop in his company's price despite finally winning European approval for the its lymphoma drug.
In many ways, TheStreet's biotechnology readers are (dis)honoring Bianco for a lifetime of investor bamboozlement and self-enrichment. The numbers that define Bianco's career as chief executive of Cell Therapeutics are stunning: Total losses of more than $1.7 billion, a 99.99999999% drop in the value of company shares and total compensation for him and his hand-picked team of executive cronies in the tens of millions of dollars.
Other than that, things have been going fine. Check the post for more, and to find out who the runners-up were. You can be sure that they're not thrilled to be on the list, either. . .
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- AstraZeneca's Move To Hot, Happening Cambridge
- Stealing A Compound, To Set Up in China
- Tecfidera's Price
- Novartis Loses the Glivec Patent Fight in India
- ChemBark Closing Down (Update: Not Really!)
- Fake Journals - But They'd Like Real Money
- Chemical Probes Versus Drugs
- Two New Books